Table 2.
Effects of introduction of pLXSN, WT-GSK-3β, and KD-GSK-3β on therapeutic sensitivity of MCF-7 breast cancer cells determined by MTT analysis (as described previous and [49]).
| Drug, Signal Transduction Inhibitor or Nutraceutical↓ | +pLXSN | +WT-GSK-3β | Fold Difference Compared to pLXSN | +KD-GSK-3β | Fold Difference Compared to pLXSN |
|---|---|---|---|---|---|
| Docetaxel | 0.7 nM | 0.12 nM | 5.8×↓ | 1.3 nM | 1.9×↑ |
| CHIR99021 | 600 nM | 100 nM | 6×↓ | 1900 nM | 3.1×↑ |
| SB415286 | 160 nM | 20 nM | 8×↓ | 500 nM | 3.1×↑ |
| Tideglusib | 800 nM | 18 nM | 44.4×↓ | 600 nM | 1.3×↓ |
| Metformin | 2000 nM | 2000 nM | 1 × | 400 nM | 5×↓ |
| Berberine | 1200 nM | 550 nM | 2.4×↓ | 1800 nM | 1.5×↑ |